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Abstract
Silencing of genes by hypermethylation contributes to cancer progression and has been shown to occur with increased
frequency at specific genomic loci. However, the precise mechanisms underlying the establishment and maintenance of
aberrant methylation marks are still elusive. The de novo DNA methyltransferase 3B (DNMT3B) has been suggested to play
an important role in the generation of cancer-specific methylation patterns. Previous studies have shown that a reduction of
DNMT3B protein levels induces antiproliferative effects in cancer cells that were attributed to the demethylation and
reactivation of tumor suppressor genes. However, methylation changes have not been analyzed in detail yet. Using RNA
interference we reduced DNMT3B protein levels in colon cancer cell lines. Our results confirm that depletion of DNMT3B
specifically reduced the proliferation rate of DNMT3B-overexpressing colon cancer cell lines. However, genome-scale DNA
methylation profiling failed to reveal methylation changes at putative DNMT3B target genes, even in the complete absence
of DNMT3B. These results show that DNMT3B is dispensable for the maintenance of aberrant DNA methylation patterns in
human colon cancer cells and they have important implications for the development of targeted DNA methyltransferase
inhibitors as epigenetic cancer drugs.
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Introduction
Epigenetic silencing of various genes by aberrant promoter
hypermethylation is a common feature of human cancer cells [1–
3]. Increasing evidence suggests that the establishment of this
hypermethylation phenotype is a directed process with specific
genes becoming preferentially methylated and inactivated in many
different cancer types. Most notably, a CpG island methylator
phenotype (CIMP) has been described, based on the methylation
status of defined marker genes [4]. CIMP is characterized by
widespread tumor-specific CpG island methylation and has been
reported in several tumor types using different methods and
different marker genes [4,5].
The mechanisms for the establishment and the maintenance of
gene-specific hypermethylation during cancer development have
not been fully elucidated yet. However, several candidate factors
have been identified which might play an important role in
recruiting DNA methyltransferases to specific genomic loci in
cancer cells. Therefore, dysregulation of recruiting factors or
alterations of gene-specific chromatin modifications involved in
recruitment could potentially lead to a hypermethylation pheno-
type in cancer. In agreement with this notion, it has been shown
that genes that are associated with components of the Polycomb
Repressive Complex 2 (PRC2) in embryonic stem (ES) cells are
frequently hypermethylated in cancer [6–8]. Additionally, in-
creased activity of DNA methyltransferases (DNMTs) in cancer
cells could potentially lead to aberrant de novo methylation.
In human cells, DNA methylation is catalyzed by DNMT1,
DNMT3A and DNMT3B [9]. During DNA replication, the so-
called maintenance methyltransferase DNMT1 methylates hemi-
methylated DNA by copying methylation marks from the parental
DNA strand to the newly synthesized daughter strand [10].
DNMT3A and DNMT3B enzymes preferentially methylate
unmethylated DNA and are therefore denoted as de novo
methyltransferases [11]. It has been shown that overexpression
of the de novo methyltransferase DNMT3B induces hypermethy-
lation of specific genes and repetitive elements in HEK293T cells
[12]. Moreover, transgenic expression of DNMT3B in mice
resulted in gene-specific de novo methylation at various loci
[13,14]. Furthermore, DNMT3B expression increases during
colorectal cancer progression and correlates positively with the
methylation level of CIMP marker genes [15,16]. These studies
implicate the de novo methyltransferase DNMT3B in the
establishment of gene-specific hypermethylation during cancer
development and progression.
In line with these findings, DNMT3B has recently been
proposed to act as a bona fide oncogene in human cancer cell
lines by correlating DNMT3B gene amplification with resistance
to DNA demethylating drugs [17]. These results further supported
the notion that overexpression of DNMT3B may contribute to
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as a candidate target for drug development in oncology. However,
only few studies have investigated the specific role of DNMT3B in
the establishment and maintenance of aberrant hypermethylation
patterns in cancer cells. A mild reduction in genomic methylation
levels has been described in DNMT3B knockout cells [18].
Moreover, DNMT3B short-term knockdown by RNAi resulted in
demethylation and reactivation of RASSF1A in A549 lung cancer
cells [19] and in demethylation of APC, RARß, and RB1 gene
promoters in PC3 prostate cancer cells [20]. Recently, differential
effects in gene re-expression and invasive behavior after siRNA-
mediated knockdown of DNMT3B or DNMT1 in breast cancer
cells have been reported [21]. Importantly, however, none of the
previous studies has systematically analyzed the impact of
DNMT3B protein reduction in parallel on proliferation and on
the global gene methylation pattern. In this study, we used
Infinium methylation arrays to interrogate the methylation level of
putative DNMT3B target genes in DNMT3B-overexpressing and
in DNMT3B-deficient colon cancer cells. While our results show
that DNMT3B knockdown impacts on the proliferation of colon
cancer cells, they also demonstrate that the enzyme is dispensable
for the hypermethylation phenotype in these cells.
Materials and Methods
Cell culture
Cell lines have been obtained from different providers: HCT-
116, Caco-2, HT-29, SW-480 from the German Collection of
Microorganisms and Cell Cultures (DSMZ, Germany); HCT-15
and SW-620 from the NCI 60-Panel; DLD-1 and WI-38 cells from
the ATCC. Human non-tumorigenic hTERT-immortalized
mammary epithelial cells with reduced levels of p53 (HMEC-
T53) were generated at Bayer Healthcare Pharmaceuticals, Berlin,
Germany (Ulbricht, U. et al. in preparation). HCT-116, Caco-2,
and HT29 cells were grown in DMEM/Ham’s F12 medium
supplemented with L-glutamine (Biochrom) and 10% fetal calf
serum (PAA). SW-480, HCT-15, SW-620, and DLD-1 cells were
cultured in RPMI 1640 medium supplemented with L-glutamine
(Biochrom) and 10% fetal calf serum (PAA). WI-38 cells were
maintained in MEM Earle’s medium supplemented with L-
glutamine (Biochrom) and 10% fetal calf serum (PAA), and
HMEC-T53 cells were grown in Mammary Epithelial Cell
Growth Medium (Promocell: C-21010) and SupplementMix
(Promocell: C-39115). HCT-116 DNMT3B knockout (3BKO),
HCT-116 DNMT1 knockout (1KO) and HCT-116 DNMT1;
DNMT3B double knockout (DKO) cells were kindly provided by
Bert Vogelstein [18]. 3BKO, 1KO, and DKO cells were cultured
in McCoy’s 5A medium supplemented with 5% L-glutamine and
10% FCS (Invitrogen); the medium of 1KO cells was additionally
supplemented with 50 mg/ml hygromycin (PAA). Early passages of
all cell lines were used for the experiments.
Expression analysis
Information on tissue-specific DNMT3B mRNA expression
levels was obtained from the Array Northern database which is
based on data of mRNA hybridized to Affymetrix arrays [22]. For
obtaining mRNA expression levels of DNMT3B in various human
normal organs, tissues and cancers, data from Affymetrix
HGU133Plus2.0 arrays were retrieved. The corresponding probe
set for DNMT3B expression was 220668_s_at. Gene expression
values are shown as geometric mean values of the expression value
on an arbitrary scale over all samples from a specific tissue type.
For quantitative real-time PCR, RNA was extracted using the
RNeasy Kit (Qiagen) and on-column genomic DNA digestion was
performed using the RNase-Free DNase I Set (Qiagen). For qRT-
PCR, 5 mg of RNA were reverse transcribed using the SuperScript
III First-Strand Synthesis System (Invitrogen) according to the
manufacturer’s protocol. Subsequently, each cDNA sample was
amplified in triplicate using the QuantiFast SYBRGreen PCR Kit
and the QuantiTect primer assays Hs_DNMT3B_1_SG for
DNMT3B and Hs_GAPDH_2_SG for GAPDH (Qiagen). The
housekeeping gene Lamin B1 was amplified using the primers
LAMIN_B1_fwd (59-CTGGAAATGTTTGCATCGAAGA-39)
and LAMIN_B1_rev (59-GCCTCCCATTGGTTGATCC-39).
The DNMT3B expression levels normalized to GAPDH or
Lamin B1 were calculated with the deltaCt method.
For immunoblot analysis, cell pellets were resuspended in PBS
(pH 7.4) containing Complete protease inhibitor cocktail (Roche)
and 25 U Benzonase Nuclease (Novagen). Cells were disrupted
using the Bioruptor Sonication system (Diagenode). Equal
amounts of protein were separated on 10% SDS-polyacrylamide
gels and transferred onto nitrocellulose membranes (Whatman).
Proteins were detected using antibodies directed against
DNMT3B (N-19, 1:500, Santa Cruz Biotechnology) and b-actin
(ab8226, 1:10,000, Abcam). Horseradish peroxidase-conjugated
secondary antibodies were visualized by enhanced chemilumines-
cence (ECL, Perkin-Elmer) and protein expression was quantified
using the ImageJ software [23]. The signal intensity of DNMT3B
was normalized to b-actin signal and the normalized signal values
were transformed in a heatmap color code.
DNMT3B RNAi knockdown
siRNA duplexes and non-targeting control siRNAs were
obtained from Qiagen (DNMT3B siRNA#1, SI00092967;
DNMT3B siRNA#2, SI00092974; DNMT3B siRNA#3,
SI03038952; DNMT3B siRNA#4, SI03068240; DNMT3B
siRNA#5, SI04987157; DNMT3B siRNA#6, SI04987164;
non-targeting control siRNA, #1027280). We confirmed in silico
that DNMT3B siRNAs target all mRNA isoforms of the active
DNMT3B enzyme. 24 hours after cell plating, cells were
transfected with 5 nM siRNAs for 72 hours using Lipofectamine
RNAiMAX reagent (Invitrogen). Transfection was repeated every
24 hours to increase knockdown efficiency. For the generation of
stable shDNMT3B clones, preselected shRNAs were cloned into
the lentiviral pGT396-Puro vectors. The shRNA sequences of the
forward oligonucleotides were as follows: sh_nontargeting: 59-
TTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACA-
CGTTCGGAGAA-39, shDNMT3B#1: 59-GACGGATGCC-
TAGAGTTTATTCAAGAGATAAACTCTAGGCATCCGTC-
39, shDNMT3B#2: 59-TGGAGATGGAGACAGTTCATT-
CAAGAGATGAACTGTCTCCATCTCCA-39. For lentivirus
production and gene transfer, HCT-116 cells were grown in
DMEM/Ham’s F12 medium supplemented with L-glutamine and
10% fetal calf serum (PAA). Selection was performed in the
presence of 1 mg/ml puromycin (Sigma). Lentiviruses were
produced by co-transfecting the respective pGT396-Puro con-
struct with lentiviral Packaging Mix (Invitrogen) into HEK-293FT
cells (Invitrogen). Viral supernatants were collected and concen-
trated by ultracentrifugation (2 h, 500006 g). Viral titers were
determined using a HIV p24 ELISA (Perkin Elmer). Transduc-
tions were carried out using p24 concentrations of 1 mg/ml for 6 h
at 37uC.
Cell viability and apoptosis analyses
Cell viability was measured in 96-well plates using the CellTiter-
Glo assay (Promega) according to the manufacturer’s instructions.
The TECAN Infinite 200 microplate reader was used for detection
of luminescence signals. For the quantitative detection of caspase
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according to the manufacturer’s protocol. Assays were performed
in 96-multiwell plates and analyzed by a TECAN Infinite 200
microplate reader. For the adjustment of cell numbers, cell
viability was determined in parallel and used for normalization.
Each sample was analyzed in quadruplicates; data are reported as
mean 6 SD.
FACS analysis
Apoptotic and necrotic cells were analyzed with the FITC
Annexin V Apoptosis Detection Kit I (BD Pharmingen). Cells
were transfected with 20 nM of indicated siRNAs, 24 hours after
cell plating. Transfection was repeated once after 24 hours to
increase knockdown efficiency. Cells were washed with cold PBS
and trypsinised 96 hours after the first transfection. After two
washes with PBS, cells were stained according to the manufactur-
er’s protocols. Samples were analyzed with a BD FACSCalibur
TM
flow cytometer. The fluorescence of 1610
4 cells was acquired and
analyzed with CellQuest Pro software (Becton Dickinson).
Annexin V-positive cells (as early marker of apoptosis) as well as
Annexin V-positive and propidium iodide (PI)-positive cells (as
early and late markers of apoptosis) were quantified.
Array-based DNA methylation analysis
Array-based gene-specific DNA methylation analysis was
performed using the Infinium HumanMethylation27 and Hu-
manMethylation450 bead chip technology (Illumina) according to
the manufacturer’s instructions. Shortly, genomic DNA of
different cell lines and siRNA-experiments (n=1) was isolated
with the DNeasy Blood and Tissue Kit (Qiagen) and deaminated
using the EZ DNA Methylation Kit (Zymo Research). Results
were analyzed using Illumina’s BeadStudio software, version
3.1.3.0. The methylation status of specific cytosines is indicated by
an average beta value (AVB) where 1 corresponds to complete
methylation and 0 to no methylation. Signals of probes with
P$0.05 were excluded from the analysis. Loci were scored as
hypermethylated if the AVB was greater than or equal to 0.8.
Since changes in AVB greater than 0.2 can be detected with 95%
statistical confidence, we used this value as a threshold to identify
significant methylation changes in our analyses [24]. Infinium
array methylation data are available in the ArrayExpress database
(www.ebi.ac.uk/arrayexpress) under the accession number E-
MTAB-719.
Statistical analyses
Results were analyzed using using Illumina’s BeadStudio
software, version 3.1.3.0 and the R stats package, version 2.14.1
[25].
Results
DNMT3B is overexpressed in different cancer types
To determine the mRNA expression of DNMT3B in various
human tissues and cancers, we analyzed the expression profiles in
the Array Northern database [22], which is based on hybridization
of RNA to the Affymetrix HGU133Plus2.0 array integrating
internally and externally generated data. DNMT3B mRNA
expression was elevated in lung, breast, cervix, ovarian, liver,
gastric and colon cancers, respectively (Figure 1A). These findings
indicate that DNMT3B mRNA is overexpressed in different
cancer tissues and suggest a role of DNMT3B in the development
or progression of various cancer types. As previous studies have
implicated DNMT3B in colon cancer development [13–16,26],
we subsequently focused on characterizing the role of DNMT3B
in colon cancer cell lines.
Using quantitative real-time PCR and immunoblotting, we
screened a panel of human colon cancer cell lines for DNMT3B
expression on the mRNA and protein level (Figure 1B, C). The
results showed increased expression of DNMT3B in a subset of
colon cancer cell lines, whereas normal human fibroblast WI-38
cells and human non-tumorigenic hTERT-immortalized mam-
mary epithelial cells with reduced levels of p53 (HMEC-T53)
showed only a very weak expression on the mRNA level and no
detectable signal in immunoblots (Figure 1B, C). The DNMT3B
mRNA expression levels were in good agreement with protein
expression levels, with Caco-2 cells having the highest DNMT3B
expression. HCT-116 and SW-620 cells expressed intermediate
levels of DNMT3B, whereas HCT-15, SW-480, DLD-1, and HT-
29 cell lines expressed low to non-detectable levels of DNMT3B.
Figure 1. DNMT3B expression in human cancer tissue and
colon cancer cell lines. (A) Array Northern analysis of DNMT3B mRNA
expression on Affymetrix HGU133Plus2.0 arrays in tumor (T) tissue
samples compared to normal (N) tissues of the same organ. n indicates
the number of analyzed samples for the specified tissue type. Data are
shown as mean6SD; *P,0.05 relative to normal tissue (N), **P,0.01
relative to normal tissue (N), ***P,0.001 relative to normal tissue (N),
determined by student’s t-test. (B) Quantitative real-time PCR analysis of
DNMT3B mRNA expression in colon cancer cell lines and normal cells
(HMEC-T53, WI-38). Expression values are means of triplicates and were
calculated relative to GAPDH expression. Error bars represent standard
errors. (C) Immunoblot of DNMT3B protein expression in lysates from
various colon cancer cell lines and normal cells (HMEC-T53, WI-38). ß-
actin was used as a loading control.
doi:10.1371/journal.pone.0036125.g001
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these cells were selected as suitable models for further analyses.
DNMT3B is required for survival of DNMT3B-
overexpressing colon cancer cells
To analyze whether DNMT3B-overexpressing cells require
DNMT3B for proliferation and survival, we performed short-term
siRNA knockdown experiments and subsequently analyzed cell
proliferation with cell viability assays. To account for the fact that
DNMT3B is expressed in many isoforms and to exclude off-target
effects, we used six different siRNAs that specifically target
different regions of the DNMT3B mRNA. Knockdown efficiency
was analyzed by quantitative RT-PCR and confirmed to be in the
range of 65% to 90% (Figure S1A–D). The knockdown of
DNMT3B specifically reduced the viability of Caco-2 and HCT-
116 (Figure 2A, B), the two cell lines that expressed high levels of
DNMT3B, whereas the viability of cell lines with low DNMT3B
expression levels such as HT-29 and DLD-1 was not affected
(Figure 2C, D). After siRNA-mediated knockdown of DNMT3B in
HCT-116 (knockdown efficiency 60% to 80%, Figure S1B), we
also analyzed caspase 3/7 activation (Figure 2E) and Annexin V
staining (Figure 2F) as markers for the induction of apoptosis. After
DNMT3B knockdown in HCT-116 cells, caspase 3/7 was induced
2–4 fold (Figure 2E) and the number of apoptotic cells (both
Annexin V as well as Annexin V- and PI-positive) was
approximately doubled when compared to cells that were
transfected with control siRNA (Figure 2F). Therefore both assays
clearly showed apoptosis induction after transient knockdown of
DNMT3B. In summary, our results demonstrate that high levels of
DNMT3B are required for the proliferation of a subset of colon
cancer cell lines, which is consistent with a proposed oncogenic
function of the protein [17].
DNMT3B overexpression does not correlate with CIMP in
colon cancer cells
Transgenic overexpression of Dnmt3b in the murine intestine has
been shown to cause DNA hypermethylation at various loci
[13,14]. In addition, it has been proposed that the hypermethyla-
tion of specific loci (CpG island methylator phenotype, CIMP)
plays an important role in the formation of many cancer types,
including colon cancer [15]. Moreover, it has recently been shown
that DNMT3B overexpression is closely associated with the
emergence of the CIMP phenotype in colorectal cancer [16]. We
therefore analyzed the relationship between DNMT3B expression
level and CIMP status using a classification based on a set of
previously established CIMP markers (CACNA1G, IGF2, NEU-
ROG1, RUNX3, SOCS1) [27]. Surprisingly, we could not detect
any correlation between the two parameters in colon cancer cell
lines. For example, CpG islands of the DNMT3B
high Caco-2 cells
were completely unmethylated at the five CIMP markers, whereas
CpG islands of the same genes were hypermethylated in the
DNMT3B
low DLD-1 cells (Figure 3A). Since this classification was
based on only five CIMP markers, we extended our analyses to an
investigation of an enlarged set of CIMP markers in three selected
cell lines, i.e. Caco-2 and HCT-116 cells with high DNMT3B
expression and HT-29 cells with a very low DNMT3B expression
level. We used Illumina Infinium 27 k methylation arrays to
obtain genome-scale methylation profiles from all three cell lines
and characterized the CIMP status using a set of 174 CpG sites
representing 67 genes that had previously been identified as CIMP
markers on the Illumina GoldenGate methylation platform [27].
Again, the methylation level of the promoter regions of these 67
genes did not correlate with DNMT3B expression levels in the
three cell lines analyzed.
Caco-2 cells, expressing the highest level of DNMT3B protein,
showed the lowest methylation of CIMP marker genes with only
23 out of 174 CpG loci (10%) being hypermethylated (AVB.0.8,
see also Material and Methods), in contrast to HT-29 cells having
53 of 174 CIMP loci (30%) with an AVB.0.8. (Figure 3B).
Infinium methylation analyses revealed the highest methylation of
CIMP markers in HCT116 cells, as indicated by a total of 104
hypermethylated loci (60%) in the heat map (Figure 3B).
Differences in the methylation of CIMP marker genes were also
nicely reflected by the median methylation of CIMP loci in Caco-
2, HCT-116, and HT-29 cells as illustrated in Figure 3C.
Altogether, our data show no general association between a high
protein expression level of DNMT3B and hypermethylation of
CIMP markers in different colon cancer cell lines. This
observation raises the possibility that the putative oncogenic
function of DNMT3B overexpression may not exclusively be
related to de novo DNA methylation of CIMP marker genes. In
addition, different CI MP patterns may also be due to cancer cell
line-specific effects.
Depletion of DNMT3B has no effect on DNA methylation
To further analyze the role of DNMT3B in DNA methylation
in colon cancer, we analyzed the effects of DNMT3B knockdown
on the genomic DNA methylation pattern. For this purpose we
used HCT-116 cells as a model, because this cell line is
characterized by a high DNMT3B expression level and has a
well-established hypermethylation phenotype. Efficient DNMT3B
knockdown by four different siRNAs failed to reveal any obvious
methylation changes on Infinium 27 k methylation arrays
(Figure 4A, B and Figure S2 A–C). Moreover, even a long-term
knockdown of DNMT3B using two different shRNA constructs
did not result in significant changes of the DNA methylation
pattern in HCT-116 cells (Figure 4C, D, and Figure S2D). Strong
knockdown efficiency was confirmed on the mRNA or on the
protein level (Figure S3A, B). Since Infinium 27 k arrays
interrogate roughly 27,000 CpG loci located in promoter regions
of about 14,000 annotated genes, we wondered whether
DNMT3B may be involved in the methylation of genomic regions
beyond those interrogated by the Infinium 27 k array. To test this
hypothesis, we used Infinium 450 k methylation arrays, which - in
addition to CpG loci in promoter regions - interrogate the
methylation status of numerous CpG sites outside of CpG islands,
addressing 99% of RefSeq genes with multiple probes per gene
[28]. However, even with a substantially increased genome
coverage we could not detect any obvious methylation changes
after shRNA-mediated long-term knockdown of DNMT3B using
450 k methylation arrays. Only 37 isolated probes indicated a
significant degree of hypomethylation, while 93 probes indicated
hypermethylation, which corresponds to a negligible fraction of
the analyzed genome (0.008% and 0.019%, respectively;
Figure 4E). In light of the fact that virtually all genes are
represented by .10 probes, these methylation changes probably
reflect isolated experimental artifacts. In agreement with these
observations, the methylation status of hypermethylated CIMP
markers did not change after long-term knockdown of DNMT3B
(Figure 4F). In summary, genome-wide methylation analyses
demonstrate that DNMT3B does not play a significant role in
maintaining methylation patterns of HCT-116 colon cancer cells.
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DNMT3B knockout cells
Since RNAi-mediated knockdown does not completely deplete
the DNMT3B protein from the cell, we wanted to rule out that
residual amounts of DNMT3B protein might be sufficient to
maintain CpG hypermethylation in HCT-116 cells. To address
this question, we analyzed the methylation pattern of HCT-116
DNMT3B knockout cells [18]. An initial analysis of these cells at
Figure 2. DNMT3B is required for survival of DNMT3B-overexpressing colon cancer cells. (A–D) Proliferation assays of colon cancer cells
expressing high (A: HCT-116, B: Caco-2) or low (C: HT-29, D: DLD-1) levels of DNMT3B. Cell viability was measured 72 h after the first transfection (see
Material and Methods) and normalized to cells transfected with non-targeting control siRNA (siCo); untr., untreated cells; lipid, transfection reagent
control. Each sample was analyzed in quadruplicates; data are shown as mean 6 SD, relative viability was used for normalization and set to 100% for
siCo treated cells. (E) Caspase 3/7 activation assay of HCT-116 cells after siRNA knockdown of DNMT3B. Each sample was analyzed in quadruplicates;
data are shown as mean6SD, relative viability was used for normalization and set to 100% for siCo treated cells. (F) FACS analysis of Annexin V-FITC
and propidium iodide (PI) staining on HCT-116 cells after siRNA knockdown of DNMT3B is shown. Annexin V positive cells and the sum of Annexin V-
positve and PI-positive cells were quantified. Values indicate means of three independent experiments. Error bars represent standard deviations.
*P,0.05 relative to control siRNA (siCo), **P,0.01 relative to control siRNA (siCo), ***P,0.001 relative to control siRNA (siCo), determined by
student’s t-test prior to normalization.
doi:10.1371/journal.pone.0036125.g002
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only a comparably small effect on the DNA methylation pattern
[18]. Our Infinium 27 k methylation data confirmed these results
and also showed that the methylation levels of 67 CIMP marker
gene promoters remained high in DNMT3B knockout cells
(Figure 5A, B). Similar findings were also obtained when we
investigated the effect of DNMT3B knockout on 543 hypermethy-
lated PRC2 target genes. These genes are frequently de novo
methylated in human cancers, including colon cancer [6–8].
However, also hypermethylated PRC2 target genes were not
significantly demethylated in DNMT3B knockout cells (Figure 5C,
D). Altogether, the data of the DNMT3B knockout cells confirm
our previous results showing that DNMT3B is not required for
maintaining the hypermethylated status of cancer-related genes in
HCT-116 cells.
Efficient demethylation of CIMP markers in DNMT1;
DNMT3B double knockout cells
Based on the analysis of both, global methylation levels and
methylation of selected loci, it has been suggested that the
combined genetic disruption of DNMT3B and DNMT1 causes a
pronounced loss of DNA methylation [18,29]. We therefore
extended our analysis to include methylation profiles from HCT-
116 double knockout cells (DKO) where both, the DNMT1 and
the DNMT3B locus, had been targeted, as well as methylation
profiles from DNMT3B-knockout (3BKO) HCT-116 cells and
DNMT1 (1KO) HCT-116 cells with a hypomorphic DNMT1
allele [18]. The results from DKO cells showed a strong
demethylation which encompassed the majority of the hyper-
methylated CIMP markers (Figure 6A). This pronounced effect
was not observed in HCT-116 cells with a reduced activity of
DNMT1, which is probably related to the hypomorphic nature of
the mutant DNMT1 allele [30,31]. We also observed a similar
result for hypermethylated PRC2 target genes which again
remained largely hypermethylated in DNMT1 hypomorphic cells
but became extensively demethylated in DKO cells (Figure 6B).
Together, these results further indicate that a combined inhibition
of DNMT3B and DNMT1 is particularly effective for the
demethylation of genes aberrantly hypermethylated in cancer.
Discussion
The potential oncogenic functions of DNA methyltransferases
represent a topic of considerable scientific interest and debate.
While it is widely accepted that aberrant DNA methylation
patterns represent a common hallmark of human cancers, it has
been surprisingly difficult to attribute a corresponding functional
significance to human DNA methyltransferase enzymes. A
landmark study in the field has shown that reduced activity of
DNMT1 suppresses intestinal tumorigenesis in a mouse colon
cancer model [32]]. However, DNMT1 is also required for
normal cellular function, e.g. for the inheritance of normal
methylation marks during S-phase [33,34] and therefore unlikely
to play a major cancer-specific role.
DNMT3A and DNMT3B are two de novo DNA methyltrans-
ferases with potentially more specialized functions in the
establishment of DNA methylation patterns during early stages
of development [35,36]. The co-ocurrence of DNMT3B overex-
pression and promoter hypermethylation observed in many
human cancers suggested that DNMT3B-mediated de novo
methylation might be functionally relevant for tumor develop-
ment. In agreement with this notion, overexpression of DNMT3B
has been shown to promote intestinal tumorigenesis in mouse
models [13].
Our results suggest that DNMT3B is required for maintaining
proliferation and for preventing apoptosis in cancer cell lines with
a high level of endogenous DNMT3B. This finding is consistent
with previous studies showing that depletion of DNMT3B induced
Figure 3. Endogenous level of DNMT3B protein expression does not correlate with CIMP status. (A) Comparison of DNMT3B expression
and CIMP status. Red color indicates high levels of DNMT3B protein expression and high levels of CIMP marker methylation, green color indicates low
levels of DNMT3B expression and low levels of CIMP marker methylation, respectively. Protein expression levels were derived from immunoblot
analysis (Figure 1C) and methylation levels of the five CIMP marker genes CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 in the cell lines were derived
from [25]. (B) Heatmap of CG methylation at 174 loci representing 67 CIMP marker genes [25] in Caco-2, HCT-116, and HT-29 colon cancer cell lines.
Average methylation was analyzed using Infinium 27 k methylation arrays. (C) Boxplots illustrate methylation levels of CIMP markers in Caco-2, HCT-
116, and HT-29 cell lines. Lines in boxes denote medians, boxes the interquartile range, and whiskers the 2.5th and 97.5th percentiles, respectively.
AVB, Average Beta value.
doi:10.1371/journal.pone.0036125.g003
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Although it was assumed that these effects would be caused by
demethylation of DNMT3B target genes, this hypothesis was not
confirmed experimentally. Our data indicate that the depletion of
DNMT3B - while inhibiting proliferation and inducting apoptosis
- does not induce any significant DNA methylation changes in
established cancer cell lines. Even the complete absence of
DNMT3B in 3BKO cells did not affect the hypermethylation
phenotype of HCT-116 colon cancer cells, indicating that the
observed antiproliferative effects of DNMT3B depletion are not
caused by DNA demethylation of putative DNMT3B target genes.
As we used high-content Infinium 27 k and 450 k methylation
arrays that interrogate the methylation status of nearly all
annotated genes in the human genome with multiple probes per
gene, we cannot exclude that the knockdown of DNMT3B may
effect the methylation of CpG loci that are not addressed by the
array. However, our results clearly indicate that the CpG island
methylator phenotype (CIMP) which has been established using
the same array-based methods before [27] is not affected by
depletion of DNMT3B in established colon cancer cell lines in
vitro.
The effect of overexpression of DNMT3B7, a C-terminally
truncated, catalytically inactive splice variant of DNMT3B, has
recently been analyzed in a mouse model of B cell lymphoma [37].
Overexpression of DNMT3B7 in Em-myc transgenic mice induced
growth of mediastinal lymphomas accompanied by increased
genomic instability, a global increase of 5-methylcytosine levels
and perturbations of specific DNA methylation patterns, where
both an increase and decrease of methylation at certain CpG
islands with high inter-tumor variability has been observed [37].
Similarly, also a conditional knockout of DNMT3B in a mouse
model of myc-induced T-cell lymphomagenesis accelerated
lymphomagenesis by increasing proliferation [38]. On the
molecular level, DNMT3B-deficient T-cell lymphomas had
increased genomic instability, a global decrease of 5-methylcyto-
Figure 4. Efficient depletion of DNMT3B has no effect on DNA
methylation. (A) DNMT3B mRNA levels were determined after siRNA
knockdown with DNMT3B siRNA #4 by quantitative RT-PCR analysis.
Expression values are means of triplicates and were calculated relative
to Lamin B1 expression. Error bars represent standard errors.
***P,0.001 relative to control siRNA, determined by student’s t-test
prior to normalization. (B) Comparison of Infinium 27 k methylation
profiles of HCT-116 cells transfected with DNMT3B siRNA #4 or control
siRNA. (C) Efficient depletion of DNMT3B protein in stably shRNA-
transduced HCT-116 cells. DNMT3B protein levels were determined by
immunoblot analysis using ß-actin as a loading control. The double
band presumably reflects the expression of two (or more) DNMT3B
isoforms. (D) Comparison of Infinium 27 k methylation profiles between
HCT-116 cells stably transduced with lentiviruses containing DNMT3B
shRNA #1 and control cells transfected with a control shRNA. (E)
Infinium 450 k methylation analysis comparing methylation profiles of
HCT-116 cells transduced with DNMT3B-shRNA #1 and control cells
transduced with a non-targeting control shRNA. (F) Heatmap based on
the Infinium 450 k data, showing hypermethylated CIMP markers in
HCT-116 cells stably transduced with shRNA #1o r#2 targeting
DNMT3B or with a non-targeting control shRNA. AVB, Average Beta
value.
doi:10.1371/journal.pone.0036125.g004
Figure 5. The hypermethylation phenotype is maintained in
DNMT3B knockout cells. (A) Heatmap based on Infinium 27 k data
illustrating the methylation levels of 67 CIMP marker genes in HCT-116
colon cancer cells and HCT-116 DNMT3B knockout cells (3BKO). (B)
Boxplot illustrating methylation levels of 67 CIMP marker genes. Lines in
boxes denote medians, boxes the interquartile range, and whiskers the
2.5th and 97.5th percentiles, respectively. (C) Heatmap based on
Infinium 27 k data illustrating the methylation levels of 543 hyper-
methylated PRC2 target genes in HCT-116 colon cancer cells and HCT-
116 DNMT3B knockout cells (3BKO). (D) Boxplot illustrating methylation
levels of PRC2 target genes. AVB, Average Beta value.
doi:10.1371/journal.pone.0036125.g005
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Analysis of global genome methylation showed that in lymphomas
of DNMT3B knockout mice hypomethylation and to a four-fold
lesser extent also hypermethylation occurred suggesting that
DNMT3B seems to play a role in hypomethylation and
hypermethylation of intragenic regions and promoters [38].
Taken together, expression of a catalytically inactive DNMT3B
variant or a conditional knockout promote tumorigenesis in myc-
driven murine models of lymphomagenesis, i.e. in cells of the
hematopoietic lineage with concomitant perturbations of DNA
methylation patterns. Besides differences in the response of
epithelial versus hematological cells towards overexpression or
knockdown of DNMT3B these data also indicate that murine
Figure 6. The hypermethylation phenotype is reversed in HCT-116 DNMT1; DNMT3B double knockout cells. (A, B) Boxplots illustrating
the methylation levels of CIMP (A) and PRC2 (B) marker genes in parental HCT-116 cells (HCT-116), HCT-116 cells lacking DNMT3B (3BKO), HCT-116
cells with a hypomorphic DNMT1 allele (1KO), and HCT-116 DNMT1; DNMT3B double knockout cells (DKO) on Infinium 27 k methylation arrays. Lines
in boxes denote medians, boxes the interquartile range, and whiskers the 2.5th and 97.5th percentiles. ***P,0.001 relative to parental HCT116 cells,
determined by a Wilcoxon rank sum test. (C) Model for the role of DNMT3B during cancer development and progression. In normal cells, CpG islands
are generally unmethylated and the corresponding genes are actively transcribed. During cancer development, certain regions become methylated
by de novo methyltransferases such as DNMT3A and DNMT3B. Once the hypermethylation phenotype is established, the methylation pattern is
maintained by the maintenance methyltransferase DNMT1 and becomes independent of DNMT3 enzymes. Only a strong reduction of overall
methyltransferase activity causes the demethylation of hypermethylated cancer genes and inhibits the re-establishment by de novo
methyltransferases.
doi:10.1371/journal.pone.0036125.g006
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[35,36] have a higher level of plasticity with regard to alterations
of DNA methylation than established cancer cells in vitro such as
the HCT-116 colon cancer cells analyzed in our siRNA and
shRNA knockdown studies. Lack of alteration of DNA methyla-
tion after DNMT3B siRNA or shRNA knockdown may therefore
be limited to the in vitro models and ‘‘differentiated’’ cancer cells
with already altered global methylation patterns. Our data does
clearly not exclude potential effects on ‘‘cancer stem cell’’-like cell
populations, which have potentially still more plasticity in their
DNA-methylation pattern.
The observed resistance to demethylation at these loci could be
explained by redundant activities in the establishment and
maintenance of DNA methylation by DNMT3A and DNMT1,
respectively, being capable of activity compensating for the loss of
DNMT3B in human cancer cells in vitro. However, this
redundancy would not include proliferation control and survival.
As such, our experiments clearly uncouple alteration of gene-
specific de novo DNA methyltransferase activity from proliferation
inhibition and apoptosis induction after knockdown of DNMT3B
protein.
The molecular mechanisms regulating DNMT3B-dependent
cell proliferation remain to be determined. In this context, it
should be noted that DNMT3B interacts with various proteins,
such as histone deacetylases, chromatin remodeling enzymes,
transcriptional regulators, sumoylating and ubiquitinating pro-
teins, and factors which play important roles in mitosis [39–42].
RNAi interference depletes DNMT3B proein levels from cells and
may induce disruption of protein complexes which contain
DNMT3B.
Thus, the alteration of gene activity, e.g. by released DNMT3B
interaction partners, by methylation-independent mechanisms
may cause changes in cellular proliferation after depletion of
DNMT3B. Similar conclusions have been drawn from experi-
ments using cell lines with experimentally reduced levels of
DNMT1 protein [43,44]. These data suggest that DNMT3B may
not exclusively be involved in DNA methylation in established
cancer cell lines but might also regulate other cellular processes by
modulating the activity or localization of interacting enzymes.
Based on these observations we developed a model to illustrate
the potential function of DNMT3B in cancer development
(Figure 6C): In normal cells, CpG islands are generally
unmethylated and the corresponding genes are actively tran-
scribed. During cancer development, certain regions become
methylated by the de novo methyltransferase DNMT3B. Once the
hypermethylation phenotype is established, the maintenance
methyltransferase activity of DNMT1 seems to be sufficient to
maintain the aberrant methylation pattern. Therefore, already
established hypermethylation patterns in cancer cells may be
independent of the de novo methylation function of DNMT3B.
This model is consistent with recent data from a mouse model
showing that induced aberrant DNA methylation, after overex-
pression of Dnmt3b, is maintained in the absence of continuous
Dnmt3b expression [14].
Importantly, our results are also relevant for optimizing
demethylation efficacy during epigenetic therapy. Established
nucleoside DNMT inhibitors like 5-azacytidine and decitabine are
characterized by low specificity and substantial drug-dependent
cytotoxicity. This necessitates the development of new, improved
DNMT inhibitors, with the goal to reverse the CIMP pattern in
e.g.colon cancer cells, to avoid the undesirable side effects in
clinical applications. While our data suggest that targeting of
DNMT1 alone is not sufficient for the demethylation of CIMP
markers, this observation can probably be explained by the
hypomorphic nature of the mutant DNMT1 allele, which still
possesses significant residual enzymatic activity [30,31]. Moreo-
ver,our data also suggest that also specifically targeting of DNM3B
alone is not sufficient for the demethylation of CIMP markers.
Based on our model, a dual specific DNMT1 and DNMT3B
inhibitor would be the most efficient approach to reverse the
hypermethylation phenotype in colon cancer cells. Inhibition of
DNMT1 is crucial for disrupting the aberrant methylation at
tumor-relevant genes and inhibition of DNMT3B is probably
needed to interfere with de novo methylation.
Supporting Information
Figure S1 Analysis of DNMT3B knockdown for cell
viability and apoptosis assays. (A–D). Knockdown efficiency
for cell viability and caspase assays was analyzed by quantitative
RT-PCR in (A) Caco-2, (B) HCT-116, (C) HT-29, and (D) DLD-1
cells. Expression values are means of triplicates and were
calculated relative to Lamin B1 expression. Error bars represent
standard errors. Normalized expression values in control siRNA
transfected cells were set as 1.0.
(TIF)
Figure S2 Infinium 27 k methylation analysis of HCT-
116 cells. (A–C) Comparison of Infinium 27 k methylation
profiles between HCT-116 cells transfected with either DNMT3B
siRNA #3, #5, or #6, and HCT-116 cells transfected with
control siRNAs, respectively. (D) Comparison of Infinium 27 k
methylation profiles between HCT-116 cells stably transduced
with lentiviruses containing DNMT3B shRNA #2 or transduced
with control shRNA.
(TIF)
Figure S3 Analysis of DNMT3B knockdown for Infinium
methylation arrays. (A) 72 h after transfection with the
indicated siRNAs, DNMT3B mRNA levels were determined by
quantitative RT-PCR analysis. Expression values are means of
triplicates and were calculated relative to Lamin B1 expression.
Error bars represent standard errors. Normalized expression
values in HCT-116 control siRNA transfected cells were set as
100%. (B) Efficient depletion of DNMT3B protein in stably
shRNA-transduced HCT-116 cells. DNMT3B protein levels were
determined by immunoblot analysis using ß-actin as a loading
control. The double band presumably reflects the expression of
two (or more) DNMT3B isoforms.
(TIF)
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